iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE – Get Free Report) reached a new 52-week high during mid-day trading on Friday. The stock traded as high as $109.43 and last traded at $108.1960, with a volume of 31,871 shares traded. The stock had previously closed at $106.61.
iShares U.S. Pharmaceuticals ETF Stock Up 1.6%
The company has a market capitalization of $1.62 billion, a price-to-earnings ratio of 17.75 and a beta of 0.47. The stock’s 50-day moving average price is $102.38 and its 200-day moving average price is $94.63.
Institutional Inflows and Outflows
Several hedge funds have recently made changes to their positions in IHE. MinichMacGregor Wealth Management LLC bought a new stake in iShares U.S. Pharmaceuticals ETF in the third quarter valued at approximately $32,098,000. Cetera Investment Advisers grew its holdings in iShares U.S. Pharmaceuticals ETF by 675.4% during the first quarter. Cetera Investment Advisers now owns 109,471 shares of the company’s stock worth $9,489,000 after buying an additional 95,353 shares in the last quarter. Virtue Capital Management LLC bought a new position in shares of iShares U.S. Pharmaceuticals ETF during the third quarter valued at about $6,239,000. Congress Asset Management Co. purchased a new position in iShares U.S. Pharmaceuticals ETF in the third quarter worth $56,000. Finally, AdvisorNet Financial Inc purchased a new stake in iShares U.S. Pharmaceuticals ETF during the third quarter worth about $5,224,000.
About iShares U.S. Pharmaceuticals ETF
iShares U.S. Pharmaceuticals ETF, formerly iShares Dow Jones U.S. Pharmaceuticals Index Fund (the Fund), is an exchange traded fund. The Fund seeks investment results that correspond generally to the price and yield performance of the Dow Jones U.S. Select Pharmaceuticals Index (the Index). The Index measures the performance of the pharmaceuticals sector of the United States equity market, and includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines, but excludes producers of vitamins.
See Also
- Five stocks we like better than iShares U.S. Pharmaceuticals ETF
- Microsoft Earnings Expose a Growing Divide in the Magnificent 7 AI Trade
- Silicon Shock: Intel’s 25% Valuation Reset
- Advanced Micro Devices’ Meta Platforms Partnership Goes Beyond a $1 Billion Investment
- Chipotle’s $32 Floor: Is a Major Stock Rebound Coming?
Receive News & Ratings for iShares U.S. Pharmaceuticals ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares U.S. Pharmaceuticals ETF and related companies with MarketBeat.com's FREE daily email newsletter.
